Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2018 ASCO Annual Meeting!


Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Type: Poster Session

Time: Sunday June 3, 8:00 AM to 11:30 AM

Location: Hall A

Nivolumab plus cisplatin/pemetrexed or cisplatin/gemcitabine as induction in resectable NSCLC.

Sub-category:
Adjuvant Therapy

Category:
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Meeting:
2018 ASCO Annual Meeting

Abstract No:
TPS8582

Poster Board Number:
Poster Session (Board #187a)

Citation:
J Clin Oncol 36, 2018 (suppl; abstr TPS8582)

Author(s): Nathaniel R. Evans, Scott Cowan, Charalambos Solomides, D. Craig Hooper, Larry Harshyne, Grace L. Lu-Yao, Hushan Yang, Linda Phan, Dawn Poller, Benjamin Leiby, Maria Werner-Wasik, Bo Lu, Jennifer Maria Johnson, Rita Susan Axelrod, Athanassios Argiris, Ralph Zinner; Thomas Jefferson University, Philadelphia, PA; Department of Pathology, Thomas Jefferson University, Philadelphia, PA; Thomas Jefferson University, Department of Neurological Surgery, Philadelphia, PA; Sidney Kimmel Cancer Center at Jefferson, Philadelphia, PA; The Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA; Thomas Jefferson University, Department of Pharmacology and Experimental Therapeutics, Philadelphia, PA, US; Thomas Jefferson University Hospital, Philadelphia, PA; Vanderbilt University Medical Center, Nashville, TN; Thomas Jefferson University, Department of Medical Oncology, Philadelphia, PA; Thomas Jefferson University, Department of Otolaryngology, Philadelphia, PA; Hygeia Hospital, Athens, Greece

Abstract Disclosures

Abstract:

Background: For patients (pts) with stage IB (≥4cm)-IIIA Non-small-cell lung cancer (NSCLC), multi-modality therapy yields a modest improvement in 5 year post-surgical overall survival (OS), with comparable benefit for induction and postoperative adjuvant chemotherapy (chemo). Induction can speed the discovery of promising regimens by using pathologic response as a surrogate for OS. About 20% of pts treated with induction chemo have major pathologic response (MPR) ( < 10% viable tumor) at primary and lymph nodes while pathologic complete responses (pCR) average 4%. MPR was strongly associated with improved OS (Hellmann MD, Lancet, 2014). PD-1 checkpoint inhibitors (CI), nivolumab (nivo), pembrolizumab (pembro), and the PD-L1 CI, atezolizumab, are established in advanced NSCLC as 2nd line therapy, and pembro is approved as a single agent as 1st line treatment of pts with PD-L1 high expressing tumors. In a phase III 1st line NSCLC study, pts with high mutational burden tumors had superior OS with nivo plus ipilimumab compared to doublet chemo. Pembro plus carboplatin with pemetrexed (P) was approved as 1st line therapy based on a randomized phase II study in advanced NSQ NSCLC showing improved clinical response and PFS compared to chemo alone with no increase in grade III toxicity. We therefore hypothesize that the addition of nivo to induction cisplatin (C) P or C gemcitabine (G) will increase the MPR rate over induction chemo alone compared to historical controls. Methods: This is an investigator initiated trial for pts with newly diagnosed clinical stage I-IIIA (stage I ≥ 4cm) SQ and NSQ NSCLC. Induction is C 75mg/m2 IV q 3w x 3 plus either P 500 mg/m2 IV q 3wks x 3 or G 1250mg/m2 IV d1, d8 q 3 wks x 3 plus nivo 360mg IV q 3w x 3. Surgery is planned 3 wks after the last dose. The primary outcome is MPR. Secondary outcomes include safety, pCR, overall clinical response rate, clinical CR, 1 year PFS, OS and exploratory outcomes assessing markers of immune bias. Enrollment will be 34 pts. Clinical trial information: NCT03366766

 
Other Abstracts in this Sub-Category:

 

1. Final overall survival for CSLC 0501: Phase 3 study of adjuvant versus neoadjuvant chemotherapy with docetaxel combined carboplatin for resectable stageⅠB-ⅢA non-small cell lung cancer.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8508 First Author: Xue-ning Yang
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

2. Comparative efficacy and safety of Pemetrexed or paclitaxel plus thoracic radiation therapy (TRT) in elderly patients with nonsquamous locally advanced NSCLC.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8509 First Author: Ge Bai
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

3. The comparison of tumor mutational burden (TMB) in patients of early and late stage lung adenocarcinoma in China.

Meeting: 2018 ASCO Annual Meeting Abstract No: 8520 First Author: Kai Zhang
Category: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers - Adjuvant Therapy

 

More...